These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 30996691)
1. Tuberculosis drug resistance in Canada: 2017. LaFreniere M; Hussain H; Vachon J Can Commun Dis Rep; 2018 Nov; 44(11):290-296. PubMed ID: 30996691 [TBL] [Abstract][Full Text] [Related]
2. Tuberculosis drug resistance in Canada: 2018. LaFreniere M; Dam D; Strudwick L; McDermott S Can Commun Dis Rep; 2020 Jan; 46(1):9-15. PubMed ID: 31930215 [TBL] [Abstract][Full Text] [Related]
3. Tuberculosis drug resistance in Canada: 2006-2016. Gallant V; Vachon J; Siu W Can Commun Dis Rep; 2017 Nov; 43(11):236-241. PubMed ID: 29770053 [TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Hersi A; Elwood K; Cowie R; Kunimoto D; Long R Can Respir J; 1999; 6(2):155-60. PubMed ID: 10322098 [TBL] [Abstract][Full Text] [Related]
5. Trends in drug-resistant tuberculosis in the United States, 1993-1996. Moore M; Onorato IM; McCray E; Castro KG JAMA; 1997 Sep; 278(10):833-7. PubMed ID: 9293991 [TBL] [Abstract][Full Text] [Related]
6. A summary of tuberculosis drug resistance in Canada, 2003-2013. McGuire M; Gallant V; Bourgeois AC; Ogunnaike-Cooke S Can Commun Dis Rep; 2015 Mar; 41(Suppl 2):8-15. PubMed ID: 31713535 [TBL] [Abstract][Full Text] [Related]
7. [Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011]. Sezen F; Albayrak N; Özkara Ş; Karagöz A; Alp A; Duyar Ağca F; İnan Süer A; Müderris T; Ceyhan İ; Durmaz R; Ertek M; Mikrobiyol Bul; 2015 Apr; 49(2):143-55. PubMed ID: 26167815 [TBL] [Abstract][Full Text] [Related]
8. Tuberculosis in Canada: 1924-2012. Gallant V; Ogunnaike-Cooke S; McGuire M Can Commun Dis Rep; 2014 Mar; 40(6):99-107. PubMed ID: 29769890 [TBL] [Abstract][Full Text] [Related]
9. Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia. Moniruzzaman A; Elwood RK; Schulzer M; FitzGerald JM Int J Tuberc Lung Dis; 2006 Aug; 10(8):844-50. PubMed ID: 16898367 [TBL] [Abstract][Full Text] [Related]
10. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. Minion J; Gallant V; Wolfe J; Jamieson F; Long R PLoS One; 2013; 8(1):e53466. PubMed ID: 23326436 [TBL] [Abstract][Full Text] [Related]
11. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850 [TBL] [Abstract][Full Text] [Related]
12. Increase in multidrug-resistant tuberculosis (MDR-TB) in Alberta among foreign-born persons: implications for tuberculosis management. Long R; Langlois-Klassen D Can J Public Health; 2013 Jan; 104(1):e22-7. PubMed ID: 23618116 [TBL] [Abstract][Full Text] [Related]
13. Drug Resistance Characteristics of Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045 [No Abstract] [Full Text] [Related]
14. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin. Taylor AB; Kurbatova EV; Cegielski JP PLoS One; 2012; 7(11):e49355. PubMed ID: 23145161 [TBL] [Abstract][Full Text] [Related]
16. A descriptive study on isoniazid resistance-associated mutations, clustering and treatment outcomes of drug-resistant tuberculosis in a high burden country. Pinhata JMW; Ferrazoli L; Mendes FF; Gonçalves MG; Rabello MCDS; Ghisi KT; Simonsen V; Cavalin RF; Lindoso AABP; de Oliveira RS Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):73-85. PubMed ID: 37943394 [TBL] [Abstract][Full Text] [Related]
17. A summary of tuberculosis in Canada, 2013. Gallant V; McGuire M; Ogunnaike-Cooke S Can Commun Dis Rep; 2015 Mar; 41(Suppl 2):2-7. PubMed ID: 31713538 [TBL] [Abstract][Full Text] [Related]
18. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848 [TBL] [Abstract][Full Text] [Related]
19. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737 [TBL] [Abstract][Full Text] [Related]